Literature DB >> 8589280

T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction.

M H Sayegh, L A Turka.   

Abstract

It is now accepted that T cells need two signals for full activation. The first is the foreign antigen itself presented by self-major histocompatibility complex and thus provides antigen specificity to the immune response. The second is a "costimulatory" signal, the best-characterized of which is provided through the T cell accessory molecule CD28. In vitro, the blockade of costimulatory signals inhibits T cell activation and induces a state of antigen-specific unresponsiveness. In vivo, agents that block CD28-mediated costimulation have proved extremely effective in inhibiting the immune response in experimental models of transplantation and autoimmune disease, providing novel strategies for use in clinical trials in the near future.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589280     DOI: 10.1681/ASN.V641143

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  14 in total

1.  The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury.

Authors:  M Takada; A Chandraker; K C Nadeau; M H Sayegh; N L Tilney
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway.

Authors:  S Sharma; K Chopra; S K Kulkarni; J N Agrewala
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

3.  Maintenance pharmacological immunosuppressive strategies in renal transplantation.

Authors:  J P Vella; M H Sayegh
Journal:  Postgrad Med J       Date:  1997-07       Impact factor: 2.401

4.  Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection.

Authors:  H Azuma; A Chandraker; K Nadeau; W W Hancock; C B Carpenter; N L Tilney; M H Sayegh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

Review 5.  Transplantation tolerance: fooling mother nature.

Authors:  M Suthanthiran
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

6.  Differential outcomes in prediabetic vs. overtly diabetic NOD mice nonmyeloablatively conditioned with costimulatory blockade.

Authors:  Larry D Bozulic; Yiming Huang; Hong Xu; Yujie Wen; Suzanne T Ildstad
Journal:  Exp Hematol       Date:  2011-07-01       Impact factor: 3.084

Review 7.  Antigen-specific immunotherapies in rheumatic diseases.

Authors:  Judit Pozsgay; Zoltán Szekanecz; Gabriella Sármay
Journal:  Nat Rev Rheumatol       Date:  2017-07-13       Impact factor: 20.543

8.  Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Jian Rong Sheng; Liangcheng Li; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  J Autoimmun       Date:  2014-01-02       Impact factor: 7.094

Review 9.  Modulating co-stimulation.

Authors:  Vissia Viglietta; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

10.  Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis.

Authors:  M E Russell; W W Hancock; E Akalin; A F Wallace; T Glysing-Jensen; T A Willett; M H Sayegh
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.